<DOC>
	<DOCNO>NCT01044719</DOCNO>
	<brief_summary>Cystic Fibrosis patient attend infective exacerbation enrol study . The trial double blind , randomise trial patient randomise 10,14 21 day antibiotic therapy , comprise tobramycin either ceftazidime meropenem .</brief_summary>
	<brief_title>Duration Antibiotics Infective Exacerbations Cystic Fibrosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>Meropenem</mesh_term>
	<mesh_term>Tobramycin</mesh_term>
	<mesh_term>Ceftazidime</mesh_term>
	<criteria>16 year old Diagnosis Cystic Fibrosis Presenting Infective exacerbation Unable give consent Allergy study medication Intolerance aminoglycoside antibiotic Pseudomonas resistant study antibiotic On active transplant list FEV1 &lt; 20 % predict Pregnancy/breastfeeding Coexistent ABPA require change treatment Coexistent mycobacterial infection A previous participant study</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
</DOC>